Introduction
A five-year clinical trial has revealed encouraging results for TransCon PTH, a hormone replacement therapy designed to treat chronic hypoparathyroidism. The therapy achieved an 82% response rate while helping most patients discontinue conventional treatments such as active vitamin D and high-dose calcium supplements.
The findings come from the Phase 2 PaTH Forward trial, where researchers evaluated the long-term safety and effectiveness of TransCon PTH, also known as palopegteriparatide. The results suggest that the therapy may address the underlying hormone deficiency rather than simply managing symptoms.
Five-Year Trial Shows Strong Results
82% of Patients Achieved the Primary Endpoint
Researchers followed 59 adults with chronic hypoparathyroidism for five years. Impressively, 56 participants, or 95%, completed the study. The trial measured a demanding composite endpoint that required patients to:
- Maintain serum calcium within the normal range
- Stop taking active vitamin D
- Reduce calcium supplementation to less than 600 mg per day
At Week 266, 82% of participants met all three criteria. Additionally, 88% maintained normal albumin-adjusted serum calcium levels, with an average value of 9.0 mg/dL.
These outcomes are notable because conventional therapy often requires lifelong calcium and vitamin D supplementation. Although these treatments help control symptoms, they do not replace the missing parathyroid hormone.
How TransCon PTH Works
Replacing the Missing Hormone
Hypoparathyroidism occurs when the body produces insufficient parathyroid hormone (PTH). This hormone regulates calcium and phosphate balance and supports the health of several organs.
TransCon PTH is a once-daily, long-acting prodrug of PTH(1-34). Unlike traditional treatments that focus mainly on calcium replacement, TransCon PTH aims to replicate the body’s natural hormone activity. As a result, it can restore more normal physiological functions across multiple organ systems.
Researchers observed improvements in:
- Serum calcium stability
- Urinary calcium regulation
- Kidney function
- Bone mineral density
- Health-related quality of life
These benefits persisted throughout the five-year study period.
Kidney, Bone, and Quality-of-Life Improvements
Kidney Function Improved Over Time
One of the most significant findings involved kidney health. Participants experienced an average increase of 9.4 mL/min/1.73 m² in estimated glomerular filtration rate (eGFR), a common measure of kidney function.
This improvement is important because prolonged use of conventional therapy can increase the risk of kidney complications, including nephrocalcinosis and renal insufficiency. Researchers found that the gains in kidney function remained stable throughout the five years of follow-up.
Bone Health Normalized
The study also demonstrated positive effects on bone mineral density (BMD). Patients initially had elevated BMD Z-scores, which gradually normalized without dropping below healthy levels.
Moreover, these changes suggest that TransCon PTH may restore bone metabolism more naturally than standard therapy. Researchers believe this balanced effect could reduce long-term skeletal complications associated with hypoparathyroidism.
Quality of Life Improved Significantly
Patients reported meaningful improvements in their daily lives. Health-related quality-of-life scores, measured using both the SF-36 and the Hypoparathyroidism Patient Experience Scale (HPES), normalized early in treatment and remained stable over five years.
Participants experienced better physical functioning, fewer symptoms, and improved overall well-being. Consequently, the therapy may provide benefits that extend far beyond laboratory values.
Safety Profile Remains Favorable
No New Safety Concerns Emerged
The long-term safety data were equally encouraging.
Researchers reported that most adverse events were mild or moderate. Importantly, no patients discontinued treatment because of drug-related side effects.
Only one participant developed temporary, low-level anti-PTH antibodies. However, these antibodies did not affect the therapy’s safety or effectiveness. No other patients developed similar immune responses during the five-year trial.
The absence of major safety issues strengthens the case for TransCon PTH as a durable long-term therapy.
What This Means for Patients
A Shift From Symptom Control to Hormone Replacement
Current hypoparathyroidism treatments mainly focus on managing low calcium levels. However, they do not replace the missing hormone that drives the disease.
TransCon PTH takes a different approach. By restoring PTH activity, the therapy addresses the root cause of hypoparathyroidism and may reduce the burden of lifelong supplementation.
Experts believe this strategy could transform care for patients who struggle to achieve stable calcium levels or experience complications from conventional treatments.
Future Outlook
The promising Phase 2 results are now supported by additional findings from the Phase 3 PaTHway trial. That study reported an 86% response rate after three and a half years, along with sustained benefits across kidney health, calcium balance, and quality of life.
As more long-term data become available, researchers will continue to assess whether these benefits remain consistent in larger patient populations. Nevertheless, the current evidence positions TransCon PTH as one of the most promising therapies for chronic hypoparathyroidism.
Conclusion
The five-year PaTH Forward trial demonstrates that TransCon PTH can deliver sustained clinical benefits for adults with hypoparathyroidism. The therapy achieved an 82% response rate, improved kidney and bone health, enhanced quality of life, and maintained a favorable safety profile.
Therefore, TransCon PTH represents a major step toward hormone replacement therapy that treats the underlying cause of the disease rather than simply managing its symptoms. If future studies confirm these findings, it could become a new standard of care for patients living with this challenging condition.
